MA50651A - Récepteurs de lymphocytes t reconnaissant p53 mutée - Google Patents

Récepteurs de lymphocytes t reconnaissant p53 mutée

Info

Publication number
MA50651A
MA50651A MA050651A MA50651A MA50651A MA 50651 A MA50651 A MA 50651A MA 050651 A MA050651 A MA 050651A MA 50651 A MA50651 A MA 50651A MA 50651 A MA50651 A MA 50651A
Authority
MA
Morocco
Prior art keywords
mutated
lymphocyte receptors
lymphocyte
receptors
Prior art date
Application number
MA050651A
Other languages
English (en)
Inventor
Drew C Deniger
Winifred M Lo
Yong-Chen Lu
Parisa Malekzadeh
Maria R Parkhurst
Anna Pasetto
Paul F Robbins
Steven A Rosenberg
Rami Yoseph
Original Assignee
Us Health
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Us Health filed Critical Us Health
Publication of MA50651A publication Critical patent/MA50651A/fr

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/10—Cellular immunotherapy characterised by the cell type used
    • A61K40/11—T-cells, e.g. tumour infiltrating lymphocytes [TIL] or regulatory T [Treg] cells; Lymphokine-activated killer [LAK] cells
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/30—Cellular immunotherapy characterised by the recombinant expression of specific molecules in the cells of the immune system
    • A61K40/32—T-cell receptors [TCR]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K40/00—Cellular immunotherapy
    • A61K40/40—Cellular immunotherapy characterised by antigens that are targeted or presented by cells of the immune system
    • A61K40/41—Vertebrate antigens
    • A61K40/42—Cancer antigens
    • A61K40/4238—Regulators of development
    • A61K40/424—Apoptosis related proteins, e.g. survivin or livin
    • A61K40/4241—Apoptosis related proteins, e.g. survivin or livin p53
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4746—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used p53
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/575—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
    • G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
    • G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
    • G01N2333/4701—Details
    • G01N2333/4748—Details p53

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Zoology (AREA)
  • Biochemistry (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Microbiology (AREA)
  • General Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Urology & Nephrology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Analytical Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • General Physics & Mathematics (AREA)
  • Physics & Mathematics (AREA)
  • Peptides Or Proteins (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
MA050651A 2017-09-29 2018-09-17 Récepteurs de lymphocytes t reconnaissant p53 mutée MA50651A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US201762565383P 2017-09-29 2017-09-29

Publications (1)

Publication Number Publication Date
MA50651A true MA50651A (fr) 2020-08-05

Family

ID=63714167

Family Applications (1)

Application Number Title Priority Date Filing Date
MA050651A MA50651A (fr) 2017-09-29 2018-09-17 Récepteurs de lymphocytes t reconnaissant p53 mutée

Country Status (20)

Country Link
US (2) US11939365B2 (fr)
EP (2) EP3688027B1 (fr)
JP (3) JP7324193B2 (fr)
KR (2) KR20250024096A (fr)
CN (2) CN111386282B (fr)
AU (2) AU2018342246B2 (fr)
BR (1) BR112020006012A2 (fr)
CA (1) CA3077024A1 (fr)
CR (4) CR20250153A (fr)
DK (1) DK3688027T3 (fr)
EA (1) EA202090757A1 (fr)
ES (1) ES3056082T3 (fr)
FI (1) FI3688027T3 (fr)
IL (1) IL273515B2 (fr)
MA (1) MA50651A (fr)
MX (4) MX421596B (fr)
PL (1) PL3688027T3 (fr)
PT (1) PT3688027T (fr)
SG (1) SG11202002636PA (fr)
WO (1) WO2019067243A1 (fr)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MD3551221T2 (ro) 2016-12-08 2022-04-30 Immatics Biotechnologies Gmbh Noi receptori de celule T și imunoterapie cu utilizarea acestora
JP7391015B2 (ja) * 2017-09-29 2023-12-04 アメリカ合衆国 Ｐ５３がん特異的変異に対して抗原特異性を有するｔ細胞を単離する方法
AU2020285380A1 (en) * 2019-05-27 2022-01-20 Provincial Health Services Authority Immunotherapy constructs targeting KRAS antigens
WO2020264269A1 (fr) * 2019-06-27 2020-12-30 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Récepteurs des lymphocytes t reconnaissant la mutation r175h ou y220c dans p53
EP3786178A1 (fr) 2019-08-30 2021-03-03 Max-Delbrück-Centrum für Molekulare Medizin in der Helmholtz-Gemeinschaft Constructions tcr spécifiques pour antigènes dérivés du virus d'epstein-barr (ebv)
CN113512124A (zh) * 2020-04-10 2021-10-19 香雪生命科学技术（广东）有限公司 一种识别hpv16的高亲和力tcr
AU2021336399A1 (en) * 2020-09-04 2023-05-18 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors recognizing r273c or y220c mutations in p53
JP2024507929A (ja) 2021-02-25 2024-02-21 アラウノス セラピューティクス インコーポレイテッド 多シストロン性発現カセットを含む組換えベクター及びそれらの使用方法
WO2022212682A2 (fr) * 2021-03-31 2022-10-06 The Johns Hopkins University Procédés et matériaux pour le ciblage d'antigènes tumoraux
EP4334340A1 (fr) * 2021-05-07 2024-03-13 The United States of America, as represented by the Secretary, Department of Health and Human Services Récepteurs de lymphocytes t reconnaissant les mutations c135y, r175h, ou m237i dans p53
WO2023050063A1 (fr) * 2021-09-28 2023-04-06 溧阳瑅赛生物医药有限公司 Tcr reconnaissant hla-a*02:01/e629-38, et son utilisation
WO2023060195A1 (fr) * 2021-10-08 2023-04-13 Baylor College Of Medicine Ciblage de mutations somatiques communes dans le cancer du sein avec une thérapie cellulaire adoptive par lymphocytes t spécifique de néo-antigène
EP4423143A4 (fr) * 2021-10-29 2025-10-01 Yafei Hou Récepteur des lymphocytes t reconnaissant la mutation r175h dans p53 et son application
WO2023150562A1 (fr) 2022-02-01 2023-08-10 Alaunos Therapeutics, Inc. Méthodes d'activation et d'expansion de lymphocytes t
US20240035027A1 (en) * 2022-05-04 2024-02-01 University Of Massachusetts Oligonucleotides for pms2 modulation
CN116063577B (zh) * 2022-11-18 2025-02-07 重庆医科大学 Tcr或其抗原结合片段及其应用
AU2024241888A1 (en) 2023-03-27 2025-10-16 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services T cell receptors targeting y220c or r175h mutation in p53
EP4750486A2 (fr) * 2023-07-25 2026-06-03 Memorial Sloan Kettering Cancer Center Récepteurs de lymphocytes t ciblant les mutations hotspot de tp53 et leurs utilisations
WO2025060149A1 (fr) * 2023-09-22 2025-03-27 上海市第一人民医院 Tcr séparé et son utilisation
WO2025226769A1 (fr) * 2024-04-24 2025-10-30 Bluesphere Bio, Inc. Récepteurs des lymphocytes t ciblant l'antigène mineur d'histocompatibilité lhr-1
WO2025250587A1 (fr) 2024-05-29 2025-12-04 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Expression de cytokine inductible pouvant être régulée par un médicament
WO2026040998A1 (fr) * 2024-08-20 2026-02-26 上海灵识质源生物技术有限公司 Peptide d'épitope mutant tp53, récepteur de lymphocytes t spécifique et utilisation associée

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6770749B2 (en) * 2000-02-22 2004-08-03 City Of Hope P53-specific T cell receptor for adoptive immunotherapy
WO2004018619A2 (fr) * 2001-06-05 2004-03-04 Altor Bioscience Corporation Molecules du recepteur des lymphocytes t se liant a la proteine p53, et leurs utilisations
US8034334B2 (en) 2002-09-06 2011-10-11 The United States Of America As Represented By The Secretary, Department Of Health And Human Services Immunotherapy with in vitro-selected antigen-specific lymphocytes after non-myeloablative lymphodepleting chemotherapy
US8383099B2 (en) 2009-08-28 2013-02-26 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Adoptive cell therapy with young T cells
US20120244133A1 (en) 2011-03-22 2012-09-27 The United States of America, as represented by the Secretary, Department of Health and Methods of growing tumor infiltrating lymphocytes in gas-permeable containers
RU2693487C2 (ru) 2013-08-07 2019-07-03 Йеда Ресеарч Энд Девелопмент Ко. Лтд. Пептиды, способные реактивировать мутанты р53
DK3105335T3 (da) * 2014-02-14 2020-01-13 Univ Texas Kimære antigenreceptorer og fremgangsmåder til fremstilling heraf
US20170158749A1 (en) * 2014-04-23 2017-06-08 Board Of Regents, The University Of Texas System Chimeric antigen receptors (car) and methods for making and using the same
PT3149031T (pt) 2014-05-29 2020-03-25 Us Health Receptores de células t anti-e7 do papilomavírus humano 16
ES2924709T3 (es) * 2014-10-02 2022-10-10 Us Health Métodos de aislamiento de receptores de células T que tienen especificidad antigénica para una mutación específica de cáncer
CN107075479A (zh) 2014-10-02 2017-08-18 美国卫生和人力服务部 分离对癌症特异性突变具有抗原特异性的t细胞的方法
WO2016141169A1 (fr) * 2015-03-03 2016-09-09 Caris Mpi, Inc. Profilage moléculaire du cancer
US10544392B2 (en) * 2015-05-01 2020-01-28 The United States Of America, As Represented By The Secretary, Department Of Health And Human Services Methods of isolating T cells and T cell receptors having antigenic specificity for a cancer-specific mutation from peripheral blood
JP6913032B2 (ja) * 2015-05-20 2021-08-04 ザ・ブロード・インスティテュート・インコーポレイテッド 共通ネオ抗原
US11047011B2 (en) 2015-09-29 2021-06-29 iRepertoire, Inc. Immunorepertoire normality assessment method and its use
WO2023108150A1 (fr) * 2021-12-10 2023-06-15 Precision Biosciences, Inc. Procédés d'immunothérapie anticancéreuse

Also Published As

Publication number Publication date
MX2020003504A (es) 2020-09-14
CN118955684A (zh) 2024-11-15
IL273515B1 (en) 2025-11-01
US20240270814A1 (en) 2024-08-15
MX421596B (es) 2025-03-14
PT3688027T (pt) 2025-12-16
AU2018342246B2 (en) 2024-08-08
JP7573075B2 (ja) 2024-10-24
PL3688027T3 (pl) 2026-04-07
US11939365B2 (en) 2024-03-26
AU2024227695A1 (en) 2024-12-05
IL273515A (en) 2020-05-31
MX2024005677A (es) 2024-06-11
EP3688027A1 (fr) 2020-08-05
JP2023159112A (ja) 2023-10-31
JP7324193B2 (ja) 2023-08-09
JP7814467B2 (ja) 2026-02-16
BR112020006012A2 (pt) 2020-10-06
KR102762272B1 (ko) 2025-02-07
CA3077024A1 (fr) 2019-04-04
EP4647442A3 (fr) 2026-03-04
KR20250024096A (ko) 2025-02-18
CR20240302A (es) 2024-11-07
CN111386282A (zh) 2020-07-07
AU2018342246A1 (en) 2020-04-16
US20200277352A1 (en) 2020-09-03
CR20240303A (es) 2024-09-04
EA202090757A1 (ru) 2020-08-21
JP2025020145A (ja) 2025-02-12
WO2019067243A1 (fr) 2019-04-04
FI3688027T3 (fi) 2025-12-09
EP4647442A2 (fr) 2025-11-12
MX2024005678A (es) 2024-06-11
JP2021500010A (ja) 2021-01-07
CR20250153A (es) 2025-06-03
KR20200064110A (ko) 2020-06-05
CR20200170A (es) 2020-11-23
IL273515B2 (en) 2026-03-01
MX2024005676A (es) 2024-06-11
ES3056082T3 (en) 2026-02-18
EP3688027B1 (fr) 2025-09-10
DK3688027T3 (da) 2025-12-15
SG11202002636PA (en) 2020-04-29
CN111386282B (zh) 2024-09-06

Similar Documents

Publication Publication Date Title
PL3688027T3 (pl) Receptory limfocytów t rozpoznające zmutowany p53
MA47359A (fr) Récepteurs de lymphocytes t à appariement amélioré
FR23C1043I2 (fr) Molécules bispécifiques de liaison à l'antigène activant les lymphocytes t
IL271435A (en) T cell receptors
MA44608A (fr) Récepteurs des lymphocytes t
PT3494133T (pt) Recetores de células t anti-kras-g12d
PT3223850T (pt) Receptores de células t anti-kras mutado
IL260151A (en) T cell receptors specific for the ny-eso-1 tumor antigen-hla-a 02 complex
IL262128A (en) T cell receptors
IL262124A (en) T cell receptors
IL262146A (en) T cell receptors
SG11202002425PA (en) Hla class ii-restricted t cell receptors against mutated ras
DK3448882T3 (da) Anti-kk-lc-1-t-cellereceptorer
EP3383893A4 (fr) Récepteur de lymphocytes t à domaine variable unique
EP3529611A4 (fr) Procédés de criblage de lymphocytes b
EP3724220A4 (fr) Récepteurs daric nkg2d
LT3433270T (lt) T ląstelių receptoriai
EP3578650A4 (fr) Nouveau récepteur des lymphocytes t
PL3661941T3 (pl) Pochodne tiazolopirydynowe jako antagoniści receptora adenozynowego
EP3527502A4 (fr) Récipient de séparation à stratification
MA46464A (fr) Polymorphes de l'agoniste de récepteur muscarinique
FI11640U1 (fi) Paloturvallinen keräyssäiliö
PT3676446T (pt) Dispositivo de separação
ES1139519Y (es) Bolsa de basura
EP3744845A4 (fr) Récepteur de lymphocyte t